Research programme: cancer therapeutics - D-Pharm

Drug Profile

Research programme: cancer therapeutics - D-Pharm

Alternative Names: DP-266; DP-388; DP-411

Latest Information Update: 08 Sep 2010

Price : $50

At a glance

  • Originator D-Pharm
  • Class Lipids
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 08 Sep 2010 This programme is still in active development
  • 06 Mar 2008 Preclinical development of DP 388 is ongoing for pancreatic cancer in Israel
  • 02 Jun 2005 Preclinical trials in Cancer in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top